HRTX

Heron Therapeutics develops and commercializes injectable medicines across oncology and pain management, with approved products including ZYNRELEF (a local anesthetic-anti-inflammatory combination for post-operative pain), CINVANTI and APONVIE (both aprepitant formulations for chemotherapy-induced nausea), and SUSTOL (a long-acting granisetron injection for nausea). Heron is in the commercial stage, actively marketing these FDA-approved products in the United States while competing against existing and emerging alternatives in their respective therapeutic areas.

Pipeline

Catalyst Calendar